Bone ingrowth into porous silicon nitride

Amedica Corporation, Salt Lake City, Utah 84108, USA.
Journal of Biomedical Materials Research Part A (Impact Factor: 2.83). 01/2009; 92(4):1598-605. DOI: 10.1002/jbm.a.32498
Source: PubMed

ABSTRACT Achieving solid skeletal attachment is a requirement for the clinical success of orthopedic implants. Porous or roughened surfaces and coatings have been developed and used with mixed success to achieve attachment due to bone ingrowth. Silicon nitride is a high performance ceramic whose strength, imaging properties, and biocompatibility make it a candidate material for orthopedic implants. A porous form of silicon nitride, cancellous-structured ceramic (CSC), has been developed. CSC is a nonresorbable, partially radiolucent porous structure that can be bonded to orthopedic implants made of silicon nitride to facilitate skeletal attachment. The purpose of this study was to quantify the extent and rate of bone ingrowth into CSC in a large animal model. Cylindrical implants were placed bilaterally using staged surgeries in the medial femoral condyle of six sheep. Condyles were retrieved after 3 and 6 months in situ and prepared for examination of bone growth under SEM. Bone grew into CSC to extents and at rates similar to those reported for other titanium porous surfaces in studies involving large animals and postmortem retrievals in humans. Bone ingrowth was observed at depths of penetration greater than 3 mm in some implants after only 12 weeks in situ. Bone ingrowth into CSC is a viable method for achieving skeletal attachment.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ceramic preforms with randomly distributed particles as reticulated porous structure which are generally used for metal infiltration as reinforcement, membranes, catalyst supports etc. Preforms are characterized by open porosity making possible their infiltration by liquid metal alloys. In this work, quartz powders using carbon black as a reducing agent were used for alpha Si3N4 powders synthesis through a carbothermal reduction and nitridation (CRN) process. The CRN process was carried out under nitrogen flow at 1,450 °C for 4 h. At high temperatures, carbon as reducing agent reacts with the oxygen of SiO2, and the resulting metallic silicon compounds with nitrogen gas to obtain silicon nitride powder. The reacted powders were used to obtain reticulated ceramic by replica method. The powders containing various bentonite ratios were mixed in water to prepare slurry. The slurry was infiltrated into a polyurethane sponge. A high porous ceramic foam (preform) structure was achieved after burn out of the sponge. All ceramic preforms were sintered to increase stiffness (in the temperature range 900–1,350 °C). The sintered ceramic foams were subjected to compressive tests. The scanning electron microscopy was used to examine the reticulated ceramic foam structure, and X-ray diffraction analysis was performed to determine phases.
    Journal of Porous Materials 12/2013; 20(6). DOI:10.1007/s10934-013-9736-9 · 1.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical outcome of lumbar spinal fusion is correlated with achievement of bony fusion. Improving interbody implant bone on-growth and in-growth may enhance fusion, limiting pseudoarthrosis, stress shielding, subsidence and implant failure. Polyetheretherketone (PEEK) and titanium (Ti) are commonly selected for interbody spacer construction. Although these materials have desirable biocompatibility and mechanical properties, they require further modification to support osseointegration. Reports of extensive research on this topic are available in biomaterial-centric published reports; however, there are few clinical studies concerning surface modification of interbody spinal implants. The current article focuses on surface modifications aimed at fostering osseointegration from a clinician's point of view. Surface modification of Ti by creating rougher surfaces, modifying its surface topography (macro and nano), physical and chemical treatment and creating a porous material with high interconnectivity can improve its osseointegrative potential and bioactivity. Coating the surface with osteoconductive materials like hydroxyapatite (HA) can improve osseointegration. Because PEEK spacers are relatively inert, creating a composite by adding Ti or osteoconductive materials like HA can improve osseointegration. In addition, PEEK may be coated with Ti, effectively bio-activating the coating.
    Orthopaedic Surgery 05/2014; 6(2). DOI:10.1111/os.12098
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the 1970s, several studies revealed the requirement for silicon in bone development, whilst bioactive silicate glasses simultaneously pioneered the current era of bioactive materials. Considerable research has subsequently focused on the chemistry and biological function of silicon in bone, demonstrating that the element has at least two separate effects in the extracellular matrix: i) interacting with glycosaminoglycans and proteoglycans during their synthesis, and ii) forming ionic substitutions in the crystal lattice structure of hydroxyapatite. In addition, the dissolution products of bioactive glass (predominantly silicic acids) have significant effects on the molecular biology of osteoblasts in vitro, regulating the expression of several genes including key osteoblastic markers, cell cycle regulators and extracellular matrix proteins. Researchers have sought to capitalise on these effects and have generated a diverse array of biomaterials which include bioactive glasses, silicon-substituted hydroxyapatites and pure, porosified silicon, but all these materials share similarities in the mechanisms that result in their bioactivity. In this review we discuss the current data obtained from original research in biochemistry and biomaterials science supporting the role of silicon in bone, comparing both the biological function of the element and analysing the evolution of silicon-containing biomaterials.
    Acta Biomaterialia 09/2014; DOI:10.1016/j.actbio.2014.09.025 · 5.68 Impact Factor